PRANA Biotechnology Ltd
Level 1, 100 Dorcas Street
South Melbourne
Victoria
3205
Tel: 61-3-9690-7892
Fax: 61-3-9690-8587
Website: http://www.pranabio.com/
Email: info@pranabio.com
192 articles about PRANA Biotechnology Ltd
-
Alterity Therapeutics Launches to Asian Investors
4/11/2019
Alterity Therapeutics Limited, is meeting this week with sophisticated investors in both Singapore and Hong Kong in the first leg of a global investor roadshow.
-
April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
-
Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy
1/31/2019
This is the first time the FDA has granted orphan designation to a drug for the treatment of MSA.
-
Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in Prana
1/2/2019
Prana Biotechnology Ltd has today announced that it has entered into a securities purchase agreement for a lead investment by Boston based Life Biosciences LLC ("Life Biosciences") to raise up to approximately A$44.5 million
-
Prana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSA
10/5/2018
PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model of Multiple System Atrophy
-
PBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement Disorders
7/9/2018
Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration
-
First Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian Diseases
7/4/2018
Prana enrols and doses its first cohort of healthy volunteers in its Phase I clinical trial
-
Prana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian Diseases
6/14/2018
PRANA Biotechnology Ltd (ASX PBT: NASDAQ PRAN) is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial.
-
PRANA Biotechnology Commences Research Collaboration With Takeda For The Treatment Of Parkinson's Disease Gastrointestinal Neuropathology
7/18/2017
-
PRANA Biotechnology's PBT434 Lowers Alpha-Synuclein And Prevents Neurodegeneration
7/5/2017
-
PRANA Biotechnology Appoints David Stamler As Chief Medical Officer To Lead Clinical Development
6/5/2017
-
PRANA Biotechnology Alzheimer's Disease Data Features At World Leading Conference
7/28/2016
-
PRANA Biotechnology Regains Compliance With NASDAQ Continued Listing Requirements; Continues To Work Towards FDA Submission
4/11/2016
-
PRANA Biotechnology Chief Scientific Advisor Receives Smithsonian American Ingenuity Award
11/16/2015
-
PRANA Biotechnology Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price Requirement
11/9/2015
-
PRANA Biotechnology Reports FY15 Financial Results
8/27/2015
-
PRANA Biotechnology Announces Safety Outcomes Of Alzheimer’s IMAGINE Extension Trial
7/1/2015
-
PRANA Biotechnology Receives $6.8 Million R&D Tax Incentive Refund
6/19/2015
-
PRANA Biotechnology Release: European Commission (EC) Approves PBT2 Orphan Designation For Huntington’s Disease
6/1/2015
-
PRANA Biotechnology Release: PBT2 Recommended For Orphan Designation In Europe
4/28/2015